Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.
The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...
Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results